Dimitriou Rozalia, Tsiridis Eleftherios, Carr Ian, Simpson Hamish, Giannoudis Peter V
Academic Department of Trauma & Orthopaedic Surgery, School of Medicine, University of Leeds, United Kingdom.
Injury. 2006 Apr;37 Suppl 1:S20-9. doi: 10.1016/j.injury.2006.02.039. Epub 2006 Apr 17.
The balance between all the signalling molecules involved in bone formation with their inhibitors and most importantly between BMPs and their antagonists is critical determinant of osteogenesis, and therefore of skeletal development, fracture repair, and bone remodelling. The main identified inhibitory molecules of the osteogenic lineage, either from studies during embryonic development or from in vitro and in vivo studies are presented in the herein study. Potential treatments using these molecules either alone or in combination with BMPs to control the bone growth and overgrowth are already under investigation aiming in treatments that mimic as much as possible the natural process of bone generation in various situations including fracture healing, osteoporosis, and osteoarthritis and other metabolic disorders, in order to more closely resemble the original tissue.
参与骨形成的所有信号分子与其抑制剂之间的平衡，最重要的是骨形态发生蛋白（BMPs）与其拮抗剂之间的平衡，是成骨作用的关键决定因素，因此也是骨骼发育、骨折修复和骨重塑的关键决定因素。本文介绍了从胚胎发育研究以及体外和体内研究中确定的主要成骨谱系抑制分子。目前正在研究单独使用这些分子或与BMPs联合使用以控制骨生长和过度生长的潜在治疗方法，旨在尽可能模拟包括骨折愈合、骨质疏松症、骨关节炎和其他代谢紊乱在内的各种情况下骨生成的自然过程，以便更接近原始组织。
